

Active substances set

Search phrase: aflibercept

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Colon and rectum cancer

Aflibercept

Aflibercept in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCR) that is resistant to or has progressed after an oxaliplatin-containing regimen.



**FULL
REIMBURSEMENT**



ESMO